0001433714-21-000004.txt : 20210223 0001433714-21-000004.hdr.sgml : 20210223 20210223160858 ACCESSION NUMBER: 0001433714-21-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210223 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210223 DATE AS OF CHANGE: 20210223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASTLIGHT HEALTH, INC. CENTRAL INDEX KEY: 0001433714 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 261989091 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36330 FILM NUMBER: 21665439 BUSINESS ADDRESS: STREET 1: 150 SPEAR STREET STREET 2: SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94105 BUSINESS PHONE: 415-671-4683 MAIL ADDRESS: STREET 1: 150 SPEAR STREET STREET 2: SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94105 FORMER COMPANY: FORMER CONFORMED NAME: VENTANA HEALTH SERVICES, INC. DATE OF NAME CHANGE: 20090831 FORMER COMPANY: FORMER CONFORMED NAME: MARIA HEALTH INC DATE OF NAME CHANGE: 20080429 8-K 1 cslt-20210223.htm 8-K cslt-20210223
false000143371400014337142021-02-232021-02-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
February 23, 2021
Date of Report (Date of earliest event reported)
CASTLIGHT HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3633026-1989091

(State or other jurisdiction of incorporation)

(Commission File Number)
(I.R.S. Employer Identification Number)
150 Spear Street, Suite 400
San Francisco, CA 94105
(Address of principal executive offices)
(415) 829-1400
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)
Not applicable

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class B Common Stock, par value $0.0001 per shareCSLTNew York Stock Exchange


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 2.02 Results of Operations and Financial Condition.

On February 23, 2021, Castlight Health, Inc. (the "Company") issued a press release announcing its results for the three and 12 months ended December 31, 2020. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by the Company with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.

The Company refers to financial measures not presented in accordance with generally accepted accounting principles in the United States (“GAAP”) in the press release. A reconciliation of these non-GAAP financial measures to the nearest comparable GAAP financial measures is contained in the press release attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

ExhibitDescription




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CASTLIGHT HEALTH, INC.
Date:February 23, 2021By:/s/ Will Bondurant
Will Bondurant
Chief Financial Officer




EX-99.1 2 exh991-pressreleaseq420.htm EX-99.1 Document

image11.jpg
Castlight Health Announces Fourth Quarter and Full Year 2020 Results


SAN FRANCISCO - February 23, 2021 - Castlight Health, Inc. (NYSE:CSLT), a leading health benefits platform provider, today announced results for its fourth quarter and full year ended December 31, 2020.

“Our strong fourth quarter performance punctuated an important year for Castlight, during which we achieved a number of strategic milestones and delivered Castlight’s best financial performance in the company’s history," said Maeve O'Meara, chief executive officer of Castlight Health. “We accomplished several key achievements in the quarter, including adding a new health plan customer, Blue Cross Blue Shield of Alabama, in December, signing a partnership with Boston Children’s Hospital to support the national vaccination effort, and delivering strong results from our first year live with Care Guides. Our swift decisions early in the year strengthened our financial position, but still enabled us to address our customers’ needs amidst the pandemic. We are confident that the foundation we have built in high-tech, high-touch navigation has us well positioned to capture share in the growing market and deliver ARR growth in 2021.”

Financial performance for the three months ended December 31, 2020 compared to the three months ended December 31, 2019 includes:
GAAP total revenue of $37.1 million, compared to $36.4 million
GAAP gross margin of 65.2%, compared to 55.3%
Non-GAAP gross margin of 68.0%, compared to 57.8%



GAAP operating loss of $1.4 million, compared to $12.2 million
Non-GAAP operating income of $2.7 million, compared to an operating loss of $8.1 million
GAAP net loss per basic and diluted share of $0.01, compared to a net loss per basic and diluted share of $0.08
Non-GAAP net income per basic and diluted share of $0.02, compared to a net loss per basic and diluted share of $0.05
Cash provided by operations of $3.0 million, compared to $4.0 million

Financial performance for the 12 months ended December 31, 2020 compared to the 12 months ended December 31, 2019 includes:

GAAP total revenue of $146.7 million, compared to $143.3 million
GAAP gross margin of 64.5%, compared to 58.8%
Non-GAAP gross margin of 67.5% compared to 61.6%
GAAP operating loss of $62.8 million, compared to a loss of $41.3 million
Non-GAAP operating income of $6.3 million, compared to a loss of $21.7 million
GAAP net loss per basic and diluted share of $0.41, compared to a net loss per basic and diluted share of $0.28
Non-GAAP net income per basic and diluted share of $0.05, compared to a net loss per basic and diluted share of $0.14
Cash used in operations of $5.6 million, compared to $17.4 million used in operations

Total cash and cash equivalents were $49.2 million as of December 31, 2020.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”




Business Outlook
For the full year 2021, the Company expects:
GAAP revenue in the range of $130 million and $135 million
Non-GAAP operating loss between $4 million and $9 million
Non-GAAP net loss per share between $0.02 and $0.06, based on approximately 160 million to 161 million shares
For the first quarter of 2021, the Company expects:

GAAP revenue in the range of $32 million and $34 million

Quarterly Conference Call
Castlight Health senior management will host a conference call to discuss its fourth quarter and full year 2020 results and business outlook today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the Company’s Investor Relations website at http://ir.castlighthealth.com. An archive of the webcast can also be accessed through the same link. The live conference call can be accessed by dialing (833) 238-7953 and the replay will be available for one week at (800) 585-8367. The conference ID number for the live call and replay is 4576726.





About Castlight Health
Castlight is on a mission to make it as easy as humanly possible for its users to navigate the healthcare system and live happier, healthier, more productive lives. Our health navigation platform connects hundreds of health vendors, benefits resources, and plan designs into one comprehensive health and wellbeing experience. We guide individuals—based on their unique profile—to the best resources available to them, whether they are healthy, chronically ill, or actively seeking medical care. Castlight transforms the employee benefit experience into a deeply personalized, yet simple, guided one, empowering better-informed patient decisions to unlock better healthcare outcomes and maximizing return on healthcare investments.

For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook.

Non-GAAP Financial Measures
To supplement Castlight Health’s financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP net income (loss) per share. Non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), and non-GAAP net income (loss) exclude goodwill impairment, stock-based compensation, certain legal expenses, amortization of intangibles, restructuring charges, capitalization and amortization of internal-use software, and lease exit and related charges.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company’s core operating results and



comparison of operating results across reporting periods, and can help enhance overall understanding of the company’s historical financial performance. However, these non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP.

The non-GAAP measures we provide may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the Company’s financial information in its entirety and not rely on a single financial measure.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP (i) operating loss and net loss per share guidance for the full year 2021 to comparable GAAP measures because we do not provide guidance for stock-based compensation expense, and (ii) capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP. The factors that may impact our future stock-based compensation expense, and capitalization and amortization of internal-use software, are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort. Factors include our market capitalization and related volatility of our stock price and our inability to project the cost or scope of internally produced software.

Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. Words such as "anticipates," "expects," "intends," "plans," "projects," "believes," "seeks," "estimates," "can," "may," "will," "would" and similar expressions identify such forward-looking statements. These



statements are not guarantees of results and should not be considered as an indication of future activity or future performance. The forward-looking statements about Castlight Health’s expectations, plans, intentions, and strategies include, but are not limited to, statements regarding certain 2021 projections, the impact of COVID-19, the success of our strategy, and our expectations for our future business and financial performance. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health’s Annual Report on Form 10-K and other documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified in their entirety by these cautionary statements and are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements, except as required by law.

Copyright 2021 Castlight Health, Inc. Castlight Health® is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.






CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(unaudited)
 
As of
December 31, 2020December 31, 2019
Assets
Current assets:
Cash and cash equivalents$49,242 $43,017 
Marketable securities— 16,411 
Accounts receivable and other, net31,740 31,397 
Prepaid expenses and other current assets3,800 4,645 
Total current assets84,782 95,470 
Property and equipment, net5,321 4,856 
Restricted cash, non-current1,144 1,144 
Deferred commissions9,556 14,718 
Deferred professional service costs4,462 6,711 
Intangible assets, net7,930 12,178 
Goodwill41,485 91,785 
Operating lease right-of-use assets, net10,238 13,906 
Other assets1,855 2,016 
Total assets$166,773 $242,784 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$5,145 $19,596 
Accrued expenses and other current liabilities7,898 10,454 
Accrued compensation8,633 8,770 
Deferred revenue6,848 10,173 
Operating lease liabilities5,789 5,914 
Total current liabilities34,313 54,907 
Deferred revenue, non-current663 572 
Debt, non-current— 1,395 
Operating lease liabilities, non-current7,446 11,823 
Other liabilities, non-current485 1,213 
Total liabilities42,907 69,910 
Stockholders’ equity 123,866 172,874 
Total liabilities and stockholders’ equity $166,773 $242,784 





CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
 
 Three Months Ended December 31,Year Ended December 31,
2020201920202019
Revenue:
Subscription$34,419 $34,723 $141,160 $137,393 
Professional services and other2,667 1,724 5,549 5,915 
Total revenue, net37,086 36,447 146,709 143,308 
Cost of revenue:
Cost of subscription(1)
7,932 9,150 34,996 34,067 
Cost of professional services and other(1)
4,989 7,150 17,046 25,007 
Total cost of revenue12,921 16,300 52,042 59,074 
Gross profit 24,165 20,147 94,667 84,234 
Operating expenses:
Sales and marketing(1)
7,713 10,664 32,026 38,597 
Research and development(1)
11,418 14,487 49,465 58,994 
General and administrative(1)
6,405 7,238 25,662 27,981 
Goodwill impairment— — 50,300 — 
Total operating expenses25,536 32,389 157,453 125,572 
Operating loss(1,371)(12,242)(62,786)(41,338)
Other income, net174 496 603 1,336 
Net loss$(1,197)$(11,746)$(62,183)$(40,002)
Net loss per share, basic and diluted$(0.01)$(0.08)$(0.41)$(0.28)
Weighted-average shares used to compute basic and diluted net loss per share
154,739 147,359 151,478 145,172 

(1)Includes stock-based compensation expense as follows:
 Three Months Ended December 31,Year Ended December 31,
 2020201920202019
Cost of revenue:
Cost of subscription$215 $179 $813 $774 
Cost of professional services and other219 216 650 953 
Sales and marketing326 175 2,028 2,142 
Research and development1,041 1,369 4,544 6,100 
General and administrative1,085 1,217 4,410 5,034 





CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
 Three Months Ended December 31,Year Ended December 31,
 2020201920202019
Operating activities:
Net loss$(1,197)$(11,746)$(62,183)$(40,002)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization1,630 1,552 6,537 5,920 
Goodwill impairment— — 50,300 — 
Stock-based compensation2,886 3,156 12,445 15,003 
Amortization of deferred commissions2,272 3,365 7,789 10,768 
Amortization of deferred professional service costs1,100 2,132 3,517 5,242 
Non-cash operating lease expense1,145 1,396 4,910 5,315 
Accretion and amortization of marketable securities— (238)
Changes in operating assets and liabilities:
Accounts receivable and other, net(1,269)4,045 (343)(4,581)
Deferred commissions(1,231)(841)(2,627)(5,344)
Deferred professional service costs(260)(385)(1,178)(1,686)
Prepaid expenses and other assets582 924 824 102 
Accounts payable426 6,900 (13,622)9,278 
Operating lease liabilities(1,558)(1,459)(5,744)(5,726)
Accrued expenses and other liabilities(245)(688)(2,821)(3,760)
Deferred revenue(3,134)(7,588)(3,234)(10,478)
Accrued compensation1,812 3,223 (137)2,795 
Net cash provided by (used in) operating activities2,959 3,992 (5,565)(17,392)
Investing activities:
Purchase of property and equipment(149)(1,241)(3,580)(1,953)
Purchase of marketable securities— (7,520)(2,994)(30,589)
Sales of marketable securities— — 2,001 — 
Maturities of marketable securities— 11,075 17,400 25,745 
Net cash (used in) provided by investing activities(149)2,314 12,827 (6,797)
Financing activities:
Proceeds from exercise of stock options92 1,136 270 3,060 
Proceeds from ESPP offering— — 371 — 
Principal payments on long-term debt(464)(465)(1,859)(1,859)
Net cash (used in) provided by financing activities(372)671 (1,218)1,201 
Net increase (decrease) in cash, cash equivalents and restricted cash
2,438 6,977 6,044 (22,988)
Cash, cash equivalents and restricted cash at beginning of period
47,948 37,365 44,342 67,330 
Cash, cash equivalents and restricted cash at end of period$50,386 $44,342 $50,386 $44,342 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$49,242 $43,017 $49,242 $43,017 
Restricted cash included in Prepaid and other current assets— 181 — 181 
Restricted cash, non-current1,144 1,144 1,144 1,144 
Total cash, cash equivalents and restricted cash$50,386 $44,342 $50,386 $44,342 




CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)


Three Months EndedYear Ended
December 31, 2020September 30, 2020December 31, 2019December 31, 2020December 31, 2019
Gross profit:
GAAP gross profit subscription$26,487 $26,056 $25,573 $106,164 $103,326 
Stock-based compensation215 224 179 813 774 
Amortization of internal-use software80 79 — 264 — 
Amortization of intangibles530 530 530 2,120 2,364 
Reduction in workforce— — — 221 — 
Non-GAAP gross profit subscription$27,312 $26,889 $26,282 $109,582 $106,464 
GAAP gross margin subscription77.0 %76.5 %73.6 %75.2 %75.2 %
Non-GAAP gross margin subscription79.4 %78.9 %75.7 %77.6 %77.5 %
GAAP gross loss professional services$(2,322)$(2,865)$(5,426)$(11,497)$(19,092)
Stock-based compensation219 171 216 650 953 
Reduction in workforce— — — 317 — 
Non-GAAP gross loss professional services$(2,103)$(2,694)$(5,210)$(10,530)$(18,139)
GAAP gross margin professional services(87)%(284)%(315)%(207)%(323)%
Non-GAAP gross margin professional services(79)%(267)%(302)%(190)%(307)%
GAAP gross profit $24,165 $23,191 $20,147 $94,667 $84,234 
Impact of non-GAAP adjustments1,044 1,004 925 4,385 4,091 
Non-GAAP gross profit $25,209 $24,195 $21,072 $99,052 $88,325 
GAAP gross margin 65.2 %66.1 %55.3 %64.5 %58.8 %
Non-GAAP gross margin 68.0 %69.0 %57.8 %67.5 %61.6 %
Operating expense:
GAAP sales and marketing$7,713 $6,158 $10,664 $32,026 $38,597 
Stock-based compensation(326)(282)(175)(2,028)(2,142)
Amortization of intangibles(528)(528)(529)(2,112)(1,601)
Reduction in workforce— — (332)— 
Non-GAAP sales and marketing$6,859 $5,350 $9,960 $27,554 $34,854 
GAAP research and development$11,418 $11,182 $14,487 $49,465 $58,994 
Stock-based compensation(1,041)(1,026)(1,369)(4,544)(6,100)
Reduction in workforce— (5)— (663)— 
Certain legal expenses— — — 191 (191)
Capitalization of internally developed software— — 80 21 80 
Non-GAAP research and development$10,377 $10,151 $13,198 $44,470 $52,783 
GAAP general and administrative$6,405 $6,341 $7,238 $25,662 $27,981 
Stock-based compensation(1,085)(1,401)(1,217)(4,410)(5,034)
Amortization of intangibles— — (16)(17)(66)
Certain legal expenses— — — — (533)
Reduction in workforce— 15 — (482)— 
Non-GAAP general and administrative$5,320 $4,955 $6,005 $20,753 $22,348 
GAAP goodwill impairment$— $— $— $50,300 $— 
Goodwill impairment— — — (50,300)— 
Non-GAAP goodwill impairment$— $— $— $— $— 
GAAP operating expense$25,536 $23,681 $32,389 $157,453 $125,572 


CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)

Impact of non-GAAP adjustments(2,980)(3,225)(3,226)(64,676)(15,587)
Non-GAAP operating expense$22,556 $20,456 $29,163 $92,777 $109,985 
Operating loss:
GAAP operating loss$(1,371)$(490)$(12,242)$(62,786)$(41,338)
Impact of non-GAAP adjustments4,024 4,229 4,151 69,061 19,678 
Non-GAAP operating income (loss)$2,653 $3,739 $(8,091)$6,275 $(21,660)
Net loss and net loss per share:
GAAP net loss$(1,197)$(447)$(11,746)$(62,183)$(40,002)
Total pre-tax impact of non-GAAP adjustments4,024 4,229 4,151 69,061 19,678 
Non-GAAP net income (loss) $2,827 $3,782 $(7,595)$6,878 $(20,324)
GAAP net loss per share, basic and diluted$(0.01)$— $(0.08)$(0.41)$(0.28)
Non-GAAP net income (loss) per share, basic and diluted$0.02 $0.02 $(0.05)$0.05 $(0.14)
Shares used in basic and diluted net loss per share computation154,739 152,146 147,359 151,478 145,172 





Castlight Media Contact:
Caroline Kawashima
press@castlighthealth.com
415-246-0313



Castlight Investor Contact:
ir@castlighthealth.com
443-213-0500






EX-101.SCH 3 cslt-20210223.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 cslt-20210223_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 cslt-20210223_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 cslt-20210223_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 cslt-20210223_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 image11.jpg begin 644 image11.jpg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end XML 9 cslt-20210223_htm.xml IDEA: XBRL DOCUMENT 0001433714 2021-02-23 2021-02-23 false 0001433714 8-K 2021-02-23 CASTLIGHT HEALTH, INC. DE 001-36330 26-1989091 150 Spear Street Suite 400 San Francisco CA 94105 415 829-1400 Class B Common Stock, par value $0.0001 per share CSLT NYSE false false false false false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Feb. 23, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 23, 2021
Entity Registrant Name CASTLIGHT HEALTH, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36330
Entity Tax Identification Number 26-1989091
Entity Address, Address Line One 150 Spear Street
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94105
City Area Code 415
Local Phone Number 829-1400
Title of 12(b) Security Class B Common Stock, par value $0.0001 per share
Trading Symbol CSLT
Security Exchange Name NYSE
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001433714
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.castlighthealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cslt-20210223.htm cslt-20210223.xsd cslt-20210223_cal.xml cslt-20210223_def.xml cslt-20210223_lab.xml cslt-20210223_pre.xml exh991-pressreleaseq420.htm http://xbrl.sec.gov/dei/2019-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cslt-20210223.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "cslt-20210223_cal.xml" ] }, "definitionLink": { "local": [ "cslt-20210223_def.xml" ] }, "inline": { "local": [ "cslt-20210223.htm" ] }, "labelLink": { "local": [ "cslt-20210223_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cslt-20210223_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cslt-20210223.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cslt", "nsuri": "http://www.castlighthealth.com/20210223", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cslt-20210223.htm", "contextRef": "i3e4db37b9ce54374b6dd88bf56831367_D20210223-20210223", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.castlighthealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cslt-20210223.htm", "contextRef": "i3e4db37b9ce54374b6dd88bf56831367_D20210223-20210223", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.castlighthealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001433714-21-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001433714-21-000004-xbrl.zip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�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